ALTUVIIIO Clinical Case: DJ

Please see full Prescribing Information at https://bit.ly/VIII-PI This clinical case study features DJ, a family man with a full-time tech job trying to maximize his skills as a drummer and enjoy quality time with his wife and young son. Wary of switching treatment, he nonetheless made the decision to switch to ALTUVIIIO® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl]. Individual case studies based on actual patient cases. Names have been changed to protect patient identity. Conclusions on the efficacy and safety of ALTUVIIIO cannot be made based on this individual-level real-world patient case data. Timestamps [00:00] Getting to Know DJ [01:16] Aspirations and Interests [03:32] Why They Switched [03:50] Life With ALTUVIIIO #casestudy #patientstory #clinicalcases #expertperspective #hemophilia #adulthemophilia #hematology INDICATION ALTUVIIIO® is indicated for use in adults and pediatric patients with hemophilia A (congenital factor VIII deficiency) for: • Routine prophylaxis to reduce the frequency of bleeding episodes • On-demand treatment and control of bleeding episodes • Perioperative management of bleeding Limitation of Use ALTUVIIIO is not indicated for the treatment of von Willebrand disease. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients. WARNINGS AND PRECAUTIONS • Allergic-type hypersensitivity reactions, including anaphylaxis, have occurred with ALTUVIIIO. Discontinue use of ALTUVIIIO if hypersensitivity reaction occurs and manage symptoms as appropriate. • Formation of neutralizing antibodies (inhibitors) to Factor VIII has been reported following administration of ALTUVIIIO. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests. • If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level. ADVERSE REACTIONS The most common adverse reactions (less than 10% of subjects) reported in clinical trials were headache and arthralgia. Please see full Prescribing Information. MAT-US-2601917-v1.0-04/2026